1.Pharmacotherapy for obesity.
Journal of the Korean Medical Association 2011;54(4):409-418
Due to its serious comorbidities and high prevalence, obesity is one of the heaviest burdens for public health. Although diet, exercise and behavioral modification are the first-line treatment for obesity, their outcomes are not satisfactory. The goal of this article is to review currently available anti-obesity drugs so that physicians may apply the principle of pharmacologic treatment for obesity to obese patients in the real clinical situation. Orlistat, phentermine, diethylpropion, mazindol, and phendimetrazine have been approved as anti-obesity drugs by Korea food and drug administration and administered to patients in Korea. Besides, several non-approved drugs, including fluoxetine, bupropion, topiramate and zonisamide, are being used for weight reduction. Among these drugs, orlistat has been studied most and is the only approved drug for long-term weight management. On the other hand, the rest of the approved drugs lack the evidence of safety issues on the long-term administration. Considering that the non-approved drugs have only a small body of clinical trial results for their efficacy and safety as anti-obesity drugs, it is not appropriate to use them as a first-line therapy in obesity. Because several new medicines and combination therapies are under investigations, more drug therapy options seem to be available in this field in coming years. Although the properly executed pharmacologic treatment is a good option for weight reduction, physicians should recognize that diet, exercise, and behavioral modification are essential to all obese patient and that pharmacologic treatment has several limitations until now.
Anti-Obesity Agents
;
Bupropion
;
Comorbidity
;
Diet
;
Diethylpropion
;
Fluoxetine
;
Fructose
;
Hand
;
Humans
;
Isoxazoles
;
Korea
;
Lactones
;
Mazindol
;
Morpholines
;
Obesity
;
Phentermine
;
Prevalence
;
Public Health
;
United States Food and Drug Administration
;
Weight Loss
2.Weight Loss Drugs Recently Approved by the FDA.
Journal of Korean Diabetes 2013;14(2):58-62
There have been many advances in obesity treatment, including life-style modification and pharmacological and surgical treatments. It seems that the most remarkable advances in obesity treatment are those of pharmacological strategies. However, weight loss medications have a long history of development. The FDA has withdrawn anti-obesity drugs such as fenfluramine, dexfenfluramine, and phenylpropylamine due to unwanted side effects. Sibutramine was voluntarily withdrawn from the market, and new drugs such as rimonabant have been suspended in the middle of clinical study due to unacceptable side effects. Last year, the FDA approved two new anti-obesity drugs for the treatment of obesity. Lorcaserin is a selective 5-hydroxytryptamine receptor 2c (5-HT2c) agonist whose pharmacological mechanism of action is similar to those of fenfluramine and dexfenfluramine. However, lorcaserin is specific for 5-HT2c, which is located almost exclusively in the CNS and is not found on heart valves. Three exciting phase 3 clinical trials for lorcaserin have been published recently. Lorcaserin has been shown to successfully result in weight reduction, and the drug was not found to lead to heart disease, as is the case with some other such drugs. Furthermore, the FDA also approved controlled release phentermine/topiramate (PHEN/TPM CR), a drug composed of immediate-release phentermine and controlled-release topiramate. Weight reduction by PHEN/TPM CR is better than any other anti-obesity drugs in the world. Along with this excellent efficacy, however, come painful side effects that clinicians should consider.
Anti-Obesity Agents
;
Benzazepines
;
Cyclobutanes
;
Dexfenfluramine
;
Fenfluramine
;
Fructose
;
Heart Diseases
;
Heart Valves
;
Obesity
;
Phentermine
;
Piperidines
;
Pyrazoles
;
Serotonin
;
United States Food and Drug Administration
;
Weight Loss
3.Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People.
Kyoung Kon KIM ; Hi Jung CHO ; Hee Cheol KANG ; Bang Bu YOUN ; Kyu Rae LEE
Yonsei Medical Journal 2006;47(5):614-625
The phentermine, an appetite suppressant, has been widely applied in Korea since 2004. However, there have been relatively few reports about the efficacy and the safety of phentermine in Korea. The aim of this study is to verify the effect of phentermine on weight reduction and the safety in Korean patients. This randomized, double-blind, placebo- controlled study had been performed between February and July, 2005, in Seoul on 68 relatively healthy obese adults whose body mass index was 25 kg/m2 or greater. They received phentermine-HCl 37.5 mg or placebo once daily with behavioral therapy for obesity. The primary endpoints were the changes of body weight and waist circumference from the baseline in the intention-to-treat population. Mean decrease of both body weight and waist circumference in phentermine-treated subjects were significantly greater than that of placebo group (weight: -6.7 +/- 2.5 kg, p < 0.001; waist circumference: -6.2 +/- 3.5 cm, p < 0.001). Significant number of subjects in phentermine group accomplished weight reduction of 5% or greater from the baseline and 10% or more (p < 0.001). There were no significant differences in systolic and diastolic blood pressure between the groups (p = 0.122 for systolic BP; p = 0.219 for diastolic BP). Dry mouth and insomnia were the only statistically significant adverse events that occurred more frequently in phentermine group. Most side effects of phentermine were mild to moderate in intensity. Short-term phentermine administration induced significant weight reduction and reduction of waist circumference without clinically problematic adverse events on relatively healthy Korean obese people.
Weight Loss/*drug effects
;
Risk Factors
;
Phentermine/administration & dosage/adverse effects/*therapeutic use
;
Obesity/*drug therapy
;
Male
;
Korea
;
Humans
;
Female
;
Double-Blind Method
;
Appetite Depressants/administration & dosage/adverse effects/*therapeutic use
;
Adult
4.Pharmacotherapy for Obesity.
Journal of Menopausal Medicine 2014;20(3):90-96
Obesity is an important risk factor for metabolic disease and various cancers. Treatments of obesity include lifestyle intervention, pharmacotherapy, and bariatric surgery. If weight loss with lifestyle intervention is only modest, pharmacotherapy might be needed. Pharmacotherapy agents can be grouped by treatment period as short term or long term use agent. Several sympathomimetic drugs such as benzphetamine, diethylpropion, phendimetrazine and phentermine, are approved for short term treatment due to their safety issues. For long term treatment, orlistat, lorcaserin, and combination of phentermine/topiramate are approved by U.S. Food and Drug Administration (FDA). Orlistat partially blocks intestinal digestion of fat, therefore producing weight loss. Lorcaserin is a serotonin 2C receptor agonist. The combination of phentermine/topiramate produces a mean weight loss of 8-10 kg. Side effects of each drug are quite different. For obesity patient, side effects are important factor when choosing drugs. The goal of this article is to review currently available anti-obesity drugs.
Anti-Obesity Agents
;
Bariatric Surgery
;
Benzphetamine
;
Diethylpropion
;
Digestion
;
Drug Therapy*
;
Humans
;
Life Style
;
Metabolic Diseases
;
Obesity*
;
Phentermine
;
Receptor, Serotonin, 5-HT2C
;
Risk Factors
;
Sympathomimetics
;
United States Food and Drug Administration
;
Weight Loss
5.Behavioral Intervention and Anti-Obesity Drug Therapy.
Korean Journal of Medicine 2013;84(5):624-628
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.
Adult
;
Advisory Committees
;
Anti-Obesity Agents
;
Benzazepines
;
Blood Glucose
;
Body Mass Index
;
Cardiovascular Diseases
;
Diethylpropion
;
Fructose
;
Humans
;
Incidence
;
Korea
;
Lactones
;
Life Expectancy
;
Mass Screening
;
Mazindol
;
Morpholines
;
Obesity
;
Phentermine
;
Risk Factors
;
United States Food and Drug Administration
;
Weight Loss